Coherus Oncology, Inc. (CHRS)

NGM – Real Time Price. Currency in USD

1.71

-0.24 (-12.31%)

At close: May 12, 2026, 4:00 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Revenue

Gross Profit

Operating Income

Net Income

Income Statement
Balance Sheet
Cash Flow

Income Statement (Annual)

Financials in millions USD. Fiscal year is January – December.

Name

2025

2024

2023

2022

Total Revenue

42M

26M

257M

211M

Cost of goods sold

-18M

-14M

-163M

-74M

Gross Profit

24M

12M

94M

137M

Operating expenses (excl. COGS)

-204M

-205M

-288M

-394M

Operating Income

-180M

-193M

-257M

Non-operating income, total

-4M

-23M

-45M

-35M

Pretax income

-183M

-215M

-238M

-292M

Equity in earnings

Taxes

380K

Non-controlling/minority interest

After tax other income/expense

Net income before discontinued operations

-183M

-215M

-238M

-292M

Coherus Oncology, Inc. (CHRS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Coherus Oncology, Inc. (CHRS)

Income Statement (Annual)

Income Statement (Annual)

Search stocks

Coherus Oncology, Inc. (CHRS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Coherus Oncology, Inc. (CHRS)

Income Statement (Annual)

Income Statement (Annual)